Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QN 0139b

Next Previous
Drug Profile

QN 0139b

Alternative Names: QN-0139b

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qihan Biotech
  • Developer Qihan Biotech; Shanghai Changzheng Hospital
  • Class CAR-NK cell therapies; Gene therapies; Immunotherapies; Skin disorder therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Systemic scleroderma

Most Recent Events

  • 25 Jun 2025 Clinical trials in Systemic scleroderma (Parenteral)
  • 25 Jun 2025 Efficacy and adverse events data from a clinical trial in Systemic scleroderma released by Qihan Biotech

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top